Pulmonary Arterial Hypertension (Pah): Real-World Treatment Patterns, Outcomes And Costs Based On World Health Organization (Who) Functional Class (Fc)

Pulmonary Arterial Hypertension (PAH) Panel

The PAH Panel provides a high quality read-out of all genes with well-established association to pulmonary arterial hypertension. Our OS-SeqTM technology provides high coverage clinical grade sequencing and enables reliable diagnostics for PAH patients with significantly lower costs and faster turnaround time (basic service TAT 21 days and Express service TAT 7-10 days). The PAH Panel has under...

Asian Implications of Aflatoxin and Dioxin Foodborne Chemical Exposures Based on World Health Organization Estimates

All people need food. Unsafe foods; however, may cause diseases ranging from diarrhea to cancer. Chemicals in food are a worldwide health concern. In 2006, the World Health Organization (WHO) organized a consultation on the global burden of foodborne diseases. Work to estimate this burden began in 2007 and was carried out by the WHO Foodborne Disease Burden Epidemiology Reference Group (FERG), ...

The World Health Organization (WHO) estimates

S outh Africa is performing well on certain selected maternal health process indicators; antenatal care attendance has remained over 90% since 1998; deliveries conducted by skilled health workers have increased from 84% in 1998 to 92% in 2003. Despite this, maternal mortality is on the increase, with the latest Saving Mothers Report showing that maternal mortality in the 2002-2004 triennium inc...

Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis

Pulmonary hypertension (PH) complicating chronic obstructive pulmonary disease (COPD-PH) and interstitial lung disease (ILD-PH) (World Health Organization [WHO] Group III PH) increases medical costs and reduces survival. Despite limited data, many clinicians are using pulmonary arterial hypertension (PAH)-specific therapy to treat WHO Group III PH patients. To further investigate the utility of...

World Health Organization (WHO): Strategy on Measuring Responsiveness